Skip to main content
. 2018 Jul 16;20(11):2598–2607. doi: 10.1111/dom.13437

Table 1.

Participant demographics and baseline characteristics (randomized analysis set)

Variable DAPA + MET (n = 314) DAPA + SAXA + MET
(n = 312)
GLIM + MET
(n = 313)
Total
(n = 939)
Women (%) 112 (35.7) 122 (39.1) 105 (33.5) 339 (36.1)
Age (years) 57.4 (9.4) 59.2 (7.9) 58.6 (8.4) 58.4 (8.6)
Weight (kg) 97.7 (18.9) 95.3 (17.4) 97.3 (17.9) 96.8 (18.1)
BMI (kg/m2) 33.1 (5.2) 32.5 (5.1) 33.0 (5.1) 32.9 (5.1)
SBP (mm Hg) 138.4 (14.3) 138.8 (14.1) 138.8 (13.2) 138.6 (13.9)
Duration of type 2 diabetes (years) 6.9 (5.2) 7.3 (5.9) 6.7 (5.1) 7.0 (5.4)
HbA1c (%) 8.3 (0.7) 8.3 (0.7) 8.3 (0.8) 8.3 (0.7)
FPG (mmol/L) 10.6 (2.3) 10.5 (2.0) 10.4 (2.1) 10.5 (2.1)
eGFR (MDRD) (mL/min/1.73m2) 87.2 (19.4) 88.0 (19.6) 86.0 (17.5) 87.1 (18.9)
C‐peptide (ng/mL) 0.93 (0.36) 0.92 (0.37) 0.93 (0.34) 0.93 (0.36)
History of hypertension (%) 251 (79.9) 253 (81.1) 256 (81.8) 760 (80.9)
Antihypertensive drug usea
n = 313 n = 312 n = 312 n = 937
ACE inhibitors (plain or combinations) 143 (45.7) 163 (52.2) 164 (52.6) 470 (50.2)
Angiotensin II antagonists (plain or combinations) 96 (30.7) 70 (22.4) 74 (23.7) 240 (25.6)
Beta‐blockers (selective) 114 (36.4) 110 (35.3) 104 (33.3) 328 (35.0)
Thiazides (plain) 39 (12.5) 41 (13.1) 48 (15.4) 128 (13.7)

Data are presented as mean (SD) or number (%).

Abbreviations: ACE, angiotensin‐converting‐enzyme; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLIM, glimepiride; HbA1c, glycated haemoglobin; MDRD, Modification of Diet in Renal Disease; MET, metformin; SAXA, saxagliptin; SBP, systolic blood pressure; SD, standard deviation.

a

Includes medications initiated after double‐blind treatment initiation or prior to double‐blind treatment initiation, but continued during the double‐blind treatment phase. Data are from the safety analysis set.